COHERUS ONCOLOGY INC (CHRS) Stock Fundamental Analysis
NASDAQ:CHRS - Nasdaq - US19249H1032 - Common Stock - Currency: USD
Taking everything into account, CHRS scores 2 out of 10 in our fundamental rating. CHRS was compared to 558 industry peers in the Biotechnology industry. Both the profitability and financial health of CHRS have multiple concerns. CHRS is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CHRS had negative earnings in the past year.
CHRS had a positive operating cash flow in the past year.
In multiple years CHRS reported negative net income over the last 5 years.
In the past 5 years CHRS reported 4 times negative operating cash flow.
1.2 Ratios
CHRS has a Return On Assets of -35.29%. This is in the better half of the industry: CHRS outperforms 61.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.29% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CHRS's Profit Margin has declined in the last couple of years.
CHRS has a Gross Margin of 56.65%. This is in the better half of the industry: CHRS outperforms 78.49% of its industry peers.
In the last couple of years the Gross Margin of CHRS has declined.
The Profit Margin and Operating Margin are not available for CHRS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.65% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
2. Health
2.1 Basic Checks
CHRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CHRS has more shares outstanding
CHRS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CHRS has been reduced compared to a year ago.
2.2 Solvency
CHRS has an Altman-Z score of -6.19. This is a bad value and indicates that CHRS is not financially healthy and even has some risk of bankruptcy.
CHRS has a worse Altman-Z score (-6.19) than 64.16% of its industry peers.
The Debt to FCF ratio of CHRS is 589.85, which is on the high side as it means it would take CHRS, 589.85 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of CHRS (589.85) is better than 90.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 589.85 | ||
| Altman-Z | -6.19 |
ROIC/WACCN/A
WACC7.63%
2.3 Liquidity
CHRS has a Current Ratio of 1.22. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
CHRS has a worse Current ratio (1.22) than 84.95% of its industry peers.
CHRS has a Quick Ratio of 1.20. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.20, CHRS is doing worse than 84.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.22 | ||
| Quick Ratio | 1.2 |
3. Growth
3.1 Past
CHRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.94%, which is quite impressive.
The earnings per share for CHRS have been decreasing by -27.39% on average. This is quite bad
CHRS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.58%.
Measured over the past years, CHRS shows a decrease in Revenue. The Revenue has been decreasing by -5.60% on average per year.
EPS 1Y (TTM)50.94%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-9.37%
Revenue 1Y (TTM)-34.58%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-90.14%
3.2 Future
Based on estimates for the next years, CHRS will show a small growth in Earnings Per Share. The EPS will grow by 6.36% on average per year.
Based on estimates for the next years, CHRS will show a decrease in Revenue. The Revenue will decrease by -2.26% on average per year.
EPS Next Y-54.13%
EPS Next 2Y1.26%
EPS Next 3Y5.25%
EPS Next 5Y6.36%
Revenue Next Year-79.27%
Revenue Next 2Y-35.7%
Revenue Next 3Y-19.73%
Revenue Next 5Y-2.26%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CHRS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHRS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
91.40% of the companies in the same industry are more expensive than CHRS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 204.96 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.26%
EPS Next 3Y5.25%
5. Dividend
5.1 Amount
No dividends for CHRS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CHRS (7/15/2025, 10:54:49 AM)
0.884
-0.07 (-6.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners51.83%
Inst Owner Change0%
Ins Owners6.33%
Ins Owner Change-0.13%
Market Cap102.48M
Analysts78.46
Price Target4.78 (440.72%)
Short Float %30.33%
Short Ratio22.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-84.26%
Min EPS beat(2)-108.91%
Max EPS beat(2)-59.6%
EPS beat(4)2
Avg EPS beat(4)-5.8%
Min EPS beat(4)-108.91%
Max EPS beat(4)92.65%
EPS beat(8)4
Avg EPS beat(8)-54.53%
EPS beat(12)6
Avg EPS beat(12)-39.33%
EPS beat(16)7
Avg EPS beat(16)-46.88%
Revenue beat(2)1
Avg Revenue beat(2)-37.04%
Min Revenue beat(2)-86.37%
Max Revenue beat(2)12.3%
Revenue beat(4)3
Avg Revenue beat(4)-13.28%
Min Revenue beat(4)-86.37%
Max Revenue beat(4)17.15%
Revenue beat(8)4
Avg Revenue beat(8)-8.84%
Revenue beat(12)4
Avg Revenue beat(12)-11.94%
Revenue beat(16)4
Avg Revenue beat(16)-11.75%
PT rev (1m)0%
PT rev (3m)-20.62%
EPS NQ rev (1m)-2.41%
EPS NQ rev (3m)-10.39%
EPS NY rev (1m)-11.38%
EPS NY rev (3m)-11.47%
Revenue NQ rev (1m)-6.98%
Revenue NQ rev (3m)-21.63%
Revenue NY rev (1m)7.24%
Revenue NY rev (3m)-47.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.52 | ||
| P/FCF | 204.96 | ||
| P/OCF | 204.96 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)0
FCFY0.49%
OCF(TTM)0
OCFY0.49%
SpS1.7
BVpS-1.58
TBVpS-2.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.29% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.65% | ||
| FCFM | 0.25% |
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
F-Score5
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 589.85 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.22 | ||
| Quick Ratio | 1.2 | ||
| Altman-Z | -6.19 |
F-Score5
WACC7.63%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.94%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-9.37%
EPS Next Y-54.13%
EPS Next 2Y1.26%
EPS Next 3Y5.25%
EPS Next 5Y6.36%
Revenue 1Y (TTM)-34.58%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-90.14%
Revenue Next Year-79.27%
Revenue Next 2Y-35.7%
Revenue Next 3Y-19.73%
Revenue Next 5Y-2.26%
EBIT growth 1Y35.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-76.46%
EBIT Next 3Y1.86%
EBIT Next 5Y7.38%
FCF growth 1Y100.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.2%
OCF growth 3YN/A
OCF growth 5YN/A